I have not written here for a while. Some of the key problems with the biomedical research enterprise that I have been thinking about of late have been described by prominent scientists in widely-circulated articles. What I would have written--at least regarding the descriptions of the problems, if not the solutions--would have been redundant.
Here is an example of one of these articles (in the op-ed section of the Wall Street Journal). Regarding the authors' description of the problems with grant review, I can only say "amen." (The article, unfortunately, may be behind the Journal's paywall.)
Here is another example. Again, regarding the overview provided and the descriptions of the problems with the current system of research funding: "amen."
No comments:
Post a Comment